Bioventus — Third Quarter 2026 Earnings Summary

Bioventus reported third-quarter 2026 revenue of $142.4 million, representing a 3% increase driven primarily by growth in its Pain Treatments segment. The company achieved GAAP earnings of $0.08 per diluted share and non-GAAP earnings of $0.17 per diluted share, while generating $20.7 million in cash from operations. Management reaffirmed its full-year adjusted earnings per share guidance of $0.75 to $0.79 and updated net sales guidance to $590 million to $595 million. Additionally, the company continues to review potential strategic alternatives and made a $15.0 million discretionary prepayment on its term loan during the quarter.